Estudio de extension abierto, de 48 semanas de duracion, para evaluar la administracion de elvucitabina en combinacion con agentes antirretrovirales de base en sujetos que hayan completado 14 dias de tratamiento en el protocolo ACH443-014A.(An open-label, 48-week extension study of elvucitabine administered in combination with background antiretroviral agents in subjects who have completed 14 days of treatment in Protocol ACH443-014A.)
Phase 1
- Conditions
- Infección crónica causada por el virus de inmunodeficiencia humana (VIH-1) (Chronic Human Immunodeficiency Virus (HIV-1) Infection)MedDRA version: 9.1Level: LLTClassification code 10008919Term: Chronic HIV infection
- Registration Number
- EUCTR2006-006194-25-ES
- Lead Sponsor
- Achillion Pharmaceuticals, Inc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
Sujetos infectados por el VIH-1, M184V positivos, que hayan completado el estudio ACH443-014A y hayan otorgado su consentimiento para participar en el protocolo ACH443-018.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Sujetos que no hayan completado el tratamiento de los 14 dias en ACH443-014A y que segun el investigador no son candidatos a recibir elvucitabine con un tratamiento base antrirretroviral.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method